Dunad Therapeutics enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies

Patrick Gunning, Acting CEO/CSO
E:?info@dunad.co.uk MEDiSTRAVA Consulting
Sylvie Berrebi, Mark Swallow PhD,?George Underwood
E:?dunad@medistrava.com?
T: +44 (0)7714 306525 SOURCE Dunad Therapeutics
